05 May 2005 : Original article
Cytological aspects of rat mammary cancer therapy with soluble tumor-associated antigens and anticancer drugsItshak Zusman
Med Sci Monit 2005; 11(5): RA173-181 :: ID: 16176
Some cytological aspects of rat mammary cancer therapy with soluble tumor-associated antigens (sTAA- p66 and p51) and the anticancer drug cyclophosphamide (CPA) are analyzed. Vaccination with sTAA results in a significant increase in the areas related to the production of T and B cells in the white pulp (germinal center and PALS) and in the marginal zone of the spleen. sTAA stimulate the production of CD8+ lymphocytes inside the tumors and in bone marrow, and of CD8+ thymocytes in the medulla of the thymus. Treatment of rats with CPA decreases the activity of lymph cells in tumors, especially of CD4+ lymphocytes. In the spleen, CPA decreases the size of areas related to the production of B and T cells. In the bone marrow, CPA affects the process of myelogenesis and causes significant substitution of cellular components with fatty tissue. The combined treatment with CPA and sTAA increases the number of lymph cells and the apoptotic index in tumors, and restored the rate of B cells producing in the spleen. Similar effect was observed in lymph nodes with accumulation of B lymphocytes in the primary and secondary follicles, and of T lymphocytes in the paracortical zone. In the thymus, CPA alone or in combination with sTAA repairs the inhibitor effect of a carcinogen on synthesis of CD4+ and CD8+ thymocytes. In combined using with CPA, sTAA activate the B- and T-lymphocyte production in the host’s immune system and decrease the toxic side-effects of a drug.
Keywords: Antigens, Neoplasm - administration & dosage, Cancer Vaccines - administration & dosage, Lymphoid Tissue - immunology, Lymphoid Tissue - pathology, Mammary Neoplasms, Experimental - immunology, Phosphoproteins - administration & dosage, Trans-Activators - administration & dosage, Animals, Antigens, Neoplasm - administration & dosage, Antineoplastic Agents, Alkylating - therapeutic use, Apoptosis - drug effects, Cancer Vaccines - therapeutic use, Combined Modality Therapy, Cyclophosphamide - therapeutic use, DNA-Binding Proteins, Lymphoid Tissue - pathology, Mammary Neoplasms, Experimental - therapy, Phosphoproteins - immunology, Rats, Solubility, Trans-Activators - immunology, Transcription Factors, Tumor Suppressor Proteins
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic?
Med Sci Monit 2022; 28:e935299
26 November 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit In Press; DOI: 10.12659/MSM.935624
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems Duri...
Med Sci Monit 2022; 28:e935299
29 Nov 2021 : Database AnalysisIntegrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcin...
Med Sci Monit In Press; DOI: 10.12659/MSM.934937
26 Nov 2021 : Clinical ResearchSerum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study
Med Sci Monit In Press; DOI: 10.12659/MSM.934007
26 Nov 2021 : Database AnalysisNetwork Pharmacology Integrated Molecular Docking Revealed the Mechanism of Jianpi Yiqi Taohua Decoction Ag...
Med Sci Monit In Press; DOI: 10.12659/MSM.933537
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700